There is limited scientific evidence linking gadolinium-based contrast agents and nephrogenic systemic fibrosis. This limited evidence is mostly the result of the limited number of studies that have been performed to test the link. 

When a potential link was discovered earlier this decade, scientists began conducting tests to determine the strength of the link. However, because of the time and resources that go into such tests, this link is still being tested.

If you have been exposed to a gadolinium-based contrast agent and contracted nephrogenic systemic fibrosis, contact the nephrogenic systemic fibrosis attorneysof Williams Kherkher at 800-761-3187. 

The FDA has approved a number of gadolinium-based contrast agents. These contrast agents include Magnevist, MultiHance, Omniscan, OptiMARK, and ProHance. 

While the use of these drugs has been associated with NSF, they still have FDA approval. One reason for maintaining this approval is that medical reports have not gathered enough information about the correlation between gadolinium and NSF. 

If you have beeen diagnosed with NSF and been exposed to a gadolinium-based contrast agent, contact the gadolimium lawyers of Williams Kherkher at 800-761-3187.